Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Dihydroergotamine (MAP0004) for Acute Migraine
NCT00623636Phase 3Completed
- Sponsor
- Allergan
- Start
- Jul 2008
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of dihydroergotamine in migraine, sponsored by Allergan. Started Jul 2008; status: completed.
02
Drugs
dihydroergotamine
03
Conditions
migraine
Beyond the preview
Go deeper on NCT00623636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00623636.